StreetInsider.com News Articles

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

Fri, 16 Oct 2026 16:01:00 -0400

WILMINGTON, Del., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Chardan Healthcare Conference taking place in New York City on October 20, 2026.

On Tuesday, October 20, 2026, at 2:00 p.m. ET, Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude and Bryant Lim, Chief Financial Officer, will participate in a fireside chat.

A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

Fri, 16 Oct 2026 16:01:00 -0400

On Tuesday, October 20, 2026, at 2:00 p.m. ET, Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude and Bryant Lim, Chief Financial Officer, will participate in a fireside chat.

A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording

H.C. Wainwright Reiterates Buy Rating on Prelude Therapeutics (PRLD)

Wed, 14 Oct 2026 07:23:56 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $8.00 price target on Prelude Therapeutics (NASDAQ: PRLD).

The analyst commented: 'This morning, Prelude announced a clinical trial collaboration and supply agreement with Eli Lilly (LLY; not rated) for supply of their CDK4/6i, abemaciclib, and oral SERD, imlunestrant; Prelude expects to begin enrolling patients in a Phase 1 trial that shall evaluate its KAT6A-selective degrader, PRT13722, both as monotherapy and in combination with abemaciclib and/or imlunestrant in 4Q26. Although competition in the KAT6-targeted landscape is stiff, with at least 12 other KAT6-targeted therapies in development, we highlight the encouraging preclinical data

Prelude Therapeutics (PRLD) Reiterated at Market Outperform by Citizens as Clinical Trial Announced

Wed, 14 Oct 2026 04:21:47 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $6.00 price target on Prelude Therapeutics (NASDAQ: PRLD).

The analyst commented, "We reiterate our Market Outperform rating and $6 price target for Prelude Therapeutics based on a platform and cash/share analysis. Yesterday, Prelude announced a clinical trial collaboration and supply agreement with Eli Lilly (LLY, NC) to evaluate PRT13722 (KAT6A degrader) in combination with Verzenio (abemaciclib, a CDK4/6 inhibitor) and Inluriyo (imlunestrant, selective estrogen receptor degrader (SERD)) in patients with HR+/HER2- breast cancer. In our view, this collaboration supports rapid advancement into combination studies by providing access to two cornerstone HR+/HER2-

Prelude and Lilly team up to test PRT13722 in breast cancer trial

Tue, 13 Oct 2026 07:01:16 -0400

Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced a clinical trial collaboration and supply agreement with Eli Lilly and Company to evaluate PRT13722, an oral KAT6A selective degrader, in combination with Lilly's abemaciclib (Verzenio) and imlunestrant (Inluriyo) in patients with HR+/HER2- breast cancer.

Under the agreement, Lilly will supply abemaciclib, a CDK4/6 kinase inhibitor, and imlunestrant, an oral estrogen receptor antagonist, for use in combination cohorts within Prelude's Phase 1 trial. The U.S. Food and Drug Administration has cleared the company to proceed with the study under its Investigational New Drug application. Prelude expects to begin enrolling patients in the fourth quarter of

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Br

Tue, 13 Oct 2026 07:01:00 -0400

Combination cohorts are part of Prelude’s Phase 1 trial evaluating PRT13722 in patients with HR+/HER2- breast cancer, on track to initiate enrollment in the fourth quarter of 2026

The collaboration is underpinned by pre-clinical data that demonstrate monotherapy efficacy for PRT13722 and synergy with both CDK4/6 inhibitors and endocrine therapies across multiple HR+ breast cancer models

WILMINGTON, Del., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced a clinical trial collaboration and supply agreement with Eli Lilly and Company (“Lilly”) for supply of its CDK4/6 kinase

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Br

Tue, 13 Oct 2026 07:01:00 -0400

Combination cohorts are part of Prelude’s Phase 1 trial evaluating PRT13722 in patients with HR+/HER2- breast cancer, on track to initiate enrollment in the fourth quarter of 2026

Evercore ISI Starts Prelude Therapeutics (PRLD) at Outperform

Fri, 18 Sep 2026 06:42:29 -0400

Evercore ISI analyst Gavin Clark-Gartner initiates coverage on Prelude Therapeutics (NASDAQ: PRLD) with a Outperform rating and a price target of $10.00.

For an analyst ratings summary and ratings history on Prelude Therapeutics click here. For more ratings news on Prelude Therapeutics click here.

Shares of Prelude Therapeutics closed at $4.57 yesterday.

JPMorgan Starts Prelude Therapeutics (PRLD) at Overweight

Thu, 17 Sep 2026 02:55:38 -0400

JPMorgan analyst Joyce Zhou initiates coverage on Prelude Therapeutics (NASDAQ: PRLD) with a Overweight rating and a price target of $12.00.

The analyst comments: “Our positive outlook on PRLD shares is driven by lead asset PRT12396, a JAK2V617F mutant selective inhibitor, currently in phase 1 for V617F+ myeloproliferative neoplasms (MPNs). PRT12396 stands to improve on currently approved JAK inhibitors by selectively targeting mutant V617F+ cells, which could lead to a wider therapeutic window. Indeed, preclinical data supports the drug’s potential to be differentiated on both safety (hematologic toxicity) and in turn efficacy / disease-modifying activity (by maintaining dose intensity over longer

JPMorgan Starts Prelude Therapeutics (PRLD) at Overweight

Thu, 17 Sep 2026 02:55:38 -0400

JPMorgan analyst Joyce Zhou initiates coverage on Prelude Therapeutics (NASDAQ: PRLD) with a Overweight rating and a price target of $12.00.

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Fri, 11 Sep 2026 07:01:00 -0400

WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place in New York City September 14-16, 2026.

On Wednesday, September 16, 2026, at 10:30 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Charles Morris, MBChB, MRCP. Chief Medical Officer, Peggy Scherle, Ph.D., Chief Scientific Officer, and Bryant Lim, Chief Financial Officer will participate in a fireside chat.

A live webcast of the fireside

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Fri, 11 Sep 2026 07:01:00 -0400

A live webcast of the fireside

Form 8-K Prelude Therapeutics For: Sep 10

Thu, 10 Sep 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260910/27045140.html

FDA clears Prelude Therapeutics to begin trial of KAT6A degrader

Thu, 10 Sep 2026 07:02:40 -0400

Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced that the U.S. Food and Drug Administration cleared the company to proceed with a Phase 1 study of PRT13722, an oral KAT6A selective degrader being developed for patients with HR-positive, HER2-negative breast cancer.

The company said it expects to begin enrolling patients in the fourth quarter of 2026, according to a press release issued Sept. 10, 2026.

The Phase 1 study is described as a first-in-human, open-label, multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of PRT13722. The drug will be assessed both as a monotherapy and in combination with endocrine

FDA clears Prelude Therapeutics to begin trial of KAT6A degrader

Thu, 10 Sep 2026 07:02:40 -0400

The company said it expects to begin enrolling patients in the fourth quarter of 2026, according to a press release issued Sept. 10, 2026.

FDA clears Prelude Therapeutics to begin trial of KAT6A degrader

Thu, 10 Sep 2026 07:02:40 -0400

The company said it expects to begin enrolling patients in the fourth quarter of 2026, according to a press release issued Sept. 10, 2026.

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

Thu, 10 Sep 2026 07:01:00 -0400

Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth quarter of 2026.

WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application (IND) for PRT13722, an oral KAT6A selective degrader being developed for the treatment of patients with HR+/HER2- breast cancer. The Company expects to begin enrolling patients in the fourth quarter of 2026.

"Recent

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

Thu, 10 Sep 2026 07:01:00 -0400

Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth quarter of 2026.

"Recent

Form 10-Q Prelude Therapeutics For: Jun 30

Tue, 11 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26901915.html

Form 10-Q Prelude Therapeutics For: Jun 30

Tue, 11 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26901915.html

Form 8-K Prelude Therapeutics For: Aug 11

Tue, 11 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260811/26901753.html

Form 8-K Prelude Therapeutics For: Aug 11

Tue, 11 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260811/26901753.html

Prelude Therapeutics Incorporated (PRLD) Tops Q2 EPS by 9c

Tue, 11 Aug 2026 07:18:33 -0400

Prelude Therapeutics Incorporated (NASDAQ: PRLD) reported Q2 EPS of ($0.14), $0.09 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $5.71 million.

For earnings history and earnings-related data on Prelude Therapeutics Incorporated (PRLD) click here.

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 07:00:00 -0400

The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Enrollment continues in Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

Current cash runway expected into the second quarter of 2028 with $155 million in cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 07:00:00 -0400

The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Enrollment continues in Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

Current cash runway expected into the second quarter of 2028 with $155 million in cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026